The United States Pharmacopeia (Usp) has launched a series of Drug Supply Vulnerability Insights series to identify and highlight vulnerabilities in the global active pharmaceutical ingredient (API) supply chain.
Usp’s insights are derived from the Global Drug Supply Map, which uses over 40 external datasets and 250 million data points to quantify the risk and resilience of the upstream drug supply chain.
Usp, a nonprofit scientific organization, develops and sets standards for US formulations, biologics, drug manufacturing, and other fields.
The first results released by the USP underscore the U.S. reliance on India’s leading API makers. Over 80% of all essential drug APIs used in the US have no domestic source, and the US relies heavily on API manufacturing facilities in India and China for key ingredients.
Source: pharmaceutical-technology.com